Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2007

Sontra Medical and Echo Therapeutics Merge

  • Sontra Medical and Echo Therapeutics merged to form a publicly held company focused on transdermal therapeutics and diagnostics. The combined entity will operate under the name Echo Therapeutics.

    “This merger is a timely combination of two late-stage and powerful transdermal drug penetration technologies,” remarks Patrick Mooney, M.D., formerly with Echo and now CEO of the new firm. Michael Wigley, Sontra’s chairman adds, “We entered into this merger based on the strategic rationale that a second and complementary platform technology would expand our opportunities for long-term growth.”

    Sontra acquired all of the outstanding shares of Echo common stock in exchange for an aggregate of 6,250,000 shares of Sontra common stock. The stockholders of Sontra and former stockholders of Echo hold approximately 65% and 35% of the combined company’s outstanding common stock, respectively.

    The newly formed Echo Therapeutics will have corporate offices in Philadelphia and R&D facilities in Franklin, MA, and Durham, NC. It will focus on improving formulations of specialty pharmaceuticals and new applications of transdermal diagnostics. The company reports having a late-stage pipeline, with one FDA-approved product, a second  candidate covered by a pending NDA, and seven pipeline programs in development covering eight indications.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »